INTRODUCTION
============

Acute kidney injury (AKI) is a global health issue, with severe episodes contributing to high rates of adverse clinical and economic outcomes \[[@gfy226-B1]\]. The incidence of AKI varies widely in reported studies, from 486 to 2147 per million per year, which likely reflects differences in case ascertainment, changing definitions and the location of patient care \[[@gfy226-B5]\]. The incidence of hospital-acquired AKI is ∼5--10 times higher than that of community-acquired cases \[[@gfy226-B9]\]. AKI is a major independent predictor of both short- and long-term mortality in multiple settings and emerging evidence suggests that it also predicts long-term risk for cardiovascular events and end-stage kidney disease (ESKD) \[[@gfy226-B4], [@gfy226-B10]\].

Despite the public health importance of AKI, most published studies to-date have focused primarily on dialysis-requiring AKI (D-AKI) \[[@gfy226-B18]\]. Evidence, mainly from the USA, has shown that the incidence of D-AKI has increased significantly in recent years, which may be related to the rising burden of acute and chronic medical illness \[[@gfy226-B18], [@gfy226-B20]\]. Non-dialysis-requiring AKI (ND-AKI) is a less well-studied entity and recent evidence suggests that the magnitude of this condition is substantially higher than D-AKI and may itself portend significant health risks \[[@gfy226-B21]\]. Although great strides have been made in advancing the epidemiology of AKI, there remain several unanswered questions. First, there is residual doubt with regards to data validity, as most published studies on annual trends have relied mainly on clinical diagnosis codes rather than laboratory-based criteria for the identification and tracking of AKI events \[[@gfy226-B22]\]*.* Second, clinical investigators have typically focused primarily on the most severe form of AKI that necessitates dialysis, with little or no data on less severe forms \[[@gfy226-B23]\]. Third, there are limited data on the burden of AKI within health systems and the distribution of AKI events across the entire health system, especially in key locations where preventive efforts may confer the greatest benefit \[[@gfy226-B23]\].

To address these gaps in our knowledge, we determined temporal trends in the incidence and severity of AKI among new entrants to the Irish health system and further explored whether any observed variation in incidence rates over time might be explained by changes in demographic characteristics, markers of health status or changes in baseline kidney function prior to AKI.

MATERIALS AND METHODS
=====================

Data source
-----------

We utilized data from the National Kidney Disease Surveillance System, which serve to monitor trends and outcomes of chronic kidney disease (CKD) and AKI in the Irish health system \[[@gfy226-B24]\]. Data sources included regional laboratory information systems, which capture all inpatient and outpatient laboratory tests within a designated region, dialysis registers that capture patients who progress to ESKD and mortality data files from the national Central Statistics Office (CSO).

Cohort participants
-------------------

We identified all patients with measured serum creatinine values from two major health regions---Northwest region (from 2005 to 2014) and Midwest region (from 1999 to 2014)---and linked laboratory data records over time using an expectation maximization (EM) algorithm-based probabilistic matching strategy \[[@gfy226-B25]\]. We selected participants with calibrated serum creatinine measurements from 1 January 2005 to 31 December 2014. Individuals with kidney failure receiving dialysis or who had missing data on age, sex and unmatched mortality records were excluded. Cohort participants who did not experience AKI were included at the time of their first valid serum creatinine measurement recorded in the health system. Cohort participants who experienced an AKI were included at the time of their first episode.

Outcome: AKI
------------

The primary outcome of interest was the incidence of AKI among new entrants into the health system. The Kidney Disease: Improving Global Outcomes (KDIGO) criteria were used to identify all AKI events from 2005 to 2014 and subclassify each by severity grade \[[@gfy226-B26]\]. The baseline serum creatinine was defined as the median creatinine value recorded within 3 months prior to the AKI event. Where creatinine values were unavailable prior to an AKI episode, we improvized by using median creatinine values recorded within 3 months following the AKI episode or the minimum creatinine value within 48 h following an AKI ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Figure S1](#sup1){ref-type="supplementary-material"}). Per the KDIGO criteria, Stage 1 AKI was defined as an increase in creatinine by 50--100% within 7 days or ≥26.5 µmol/L above baseline within 48 h, Stage 2 as an increase of 100--200% above baseline creatinine and Stage 3 as a ≥200% increase or an increase ≥354 µmol/L.

Primary exposure variable
-------------------------

The primary exposure variable was calendar year from 2005 to 2014.

Covariates
----------

Baseline data on all participants were measured at the time of study inclusion. Serum creatinine was measured using the modified kinetic Jaffe method and creatinine values were calibrated to be traceable to an isotope dilution mass spectrometry (IDMS) reference measurement procedure to ensure standardization. Serum creatinine values were used to determine estimated glomerular filtration rate (eGFR; in mL/min/1.73 m^2^) for patients using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation and the Modification of Diet in Renal Disease (MDRD) equation for sensitivity analysis \[[@gfy226-B27], [@gfy226-B28]\]. CKD was defined according to the kidney disease dialysis quality outcome initiative guidelines based on eGFR measurements \[[@gfy226-B9]\]. Data were captured on an extensive list of laboratory measures including indicators of inflammation \[C-reactive protein, erythrocyte sedimentation rate (ESR), white cell count and subtypes\], nutrition (serum albumin and total protein) and bone biomarkers (serum calcium and phosphate). The location of medical supervision was defined as the location where the creatinine test was ordered by the supervising physician and categorized as inpatient facility (IP), outpatient facility (OP), general practice (GP) and emergency room (ER). The identification of these locations was considered important to explore relationships between the site of medical supervision and the frequency of AKI events. The county of residence was extracted from the patient administration system, which allowed us to classify patients by geography. The principal counties served by the Northwest region of Ireland included Donegal, Sligo and Leitrim while those served by the Midwest region included Clare, Limerick and Tipperary.

Statistical analysis
--------------------

Continuous variables are presented as mean ± standard deviation (SD) or median and interquartile range (IQR), as appropriate, while categorical variables are given as event numbers with percentages. Group comparisons for continuous variables were performed using the Kruskal--Wallis test while group comparisons were performed with the chi-squared test.

Poisson regression utilizing robust standard error estimated incident rates of AKI within the health system and rates were expressed as events per 100 person-years for the entire cohort and for selected subgroups across calendar years. Incidence rates of AKI were compared across calendar years using the 2005 year as the referent with the generation of incidence rate ratios (IRRs). Univariable and multivariable logistic regression models were developed to compare the likelihood of the first AKI across the years 2005--2014 with 2005 as the referent year. A purposeful selection process was employed in model development. Associations were expressed as odds ratios (ORs) and 95% confidence intervals (CIs); a cut-off point of *α* = 0.05 was used to assess for statistical significance. We assessed whether the likelihood of an AKI differed by age, sex and eGFR across calendar years by including interaction terms. All analyses were performed using R statistical software (R Foundation for Statistical Computing, Vienna, Austria) \[[@gfy226-B26]\].

Sensitivity analysis
--------------------

Sensitivity analyses were conducted to evaluate the robustness of our results. First, we restricted the definition of an AKI event to incorporate creatinine values recorded prior to a potential AKI episode to remove possible bias introduced by the inclusion of post-AKI creatinine concentrations. Second, we examined to what extent AKI event rates and annual trends were influenced by the definition of baseline creatinine concentration prior to AKI. For this we substituted the median creatinine value with the mean creatinine concentration and repeated the entire analysis. Finally, we determined whether our definition of eGFR altered observed trends by replacing the CKD-EPI equation with the MDRD equation.

Ethics approval
---------------

The study was approved by the Ethics Committee at University Hospital Limerick.

RESULTS
=======

Baseline characteristics of the study cohort
--------------------------------------------

The construction of the final study cohort from the Northwest and Midwest regions of Ireland is shown in [Figure 1](#gfy226-F1){ref-type="fig"}. There were 40 786 (9%) laboratory-proven episodes of AKI among 451 646 patients from 2005 to 2014 ([Table 1](#gfy226-T1){ref-type="table"}). Patients who experienced an AKI episode were on average older and male, had higher serum creatinine concentrations and lower eGFR values at baseline (P* *\<* *0.001) and had significantly higher levels of inflammatory markers and lower serum albumin levels. Most AKI episodes occurred in patients who were hospitalized as IP. Among all AKI episodes, Stage 1 occurred most frequently (81.3%), followed by Stage 2 (11.6%) and Stage 3 (7.1%). Patients who sustained a Stage 3 AKI event had baseline characteristics that reflected an older and sicker cohort ([Table 2](#gfy226-T2){ref-type="table"}).

![A Strengthening the Reporting of Observational Studies in Epidemiology flow diagram to illustrate cohort construction. The final data set (*n* = 451 646) captured information on demographic characteristics, county of residence, primary location of patient supervision, laboratory measures of health status, dialysis indicator variables and death.](gfy226f1){#gfy226-F1}

###### 

Patient characteristics at baseline by the presence of AKI

  Variable                                                                                 *N*        No AKI            AKI        P-value
  ------------------------------------------------------------------------------------- --------- --------------- --------------- ---------
  Patients, *n* (%)                                                                      451 646   410 860 (91)     40 786 (9)    
  Demographic characteristics                                                                                                     
   Age at baseline (years), mean (SD)                                                    451 646    44.8 (17.5)     67.5 (18.1)    \<0.001
   Age group categories (years), %                                                                                                
    18--39                                                                               184 572       97.7             2.3       
    40--59                                                                               148 651       95.3             4.7       
    60--80                                                                               94 489        80.4            19.6       
    \>80                                                                                 23 934        53.9            46.1        \<0.001
   Gender, %                                                                                                                      
    Women                                                                                241 696       91.7             8.3       
    Men                                                                                  209 950       90.1             9.9        \<0.001
  Geographic factors, %                                                                                                           
    County of residence                                                                                                           
     Donegal                                                                             119 025       90.9             9.1       
     Sligo                                                                               56 521        91.2             8.8       
     Leitrim                                                                             26 154        91.6             8.4       
     Limerick                                                                            84 183        89.1            10.9       
     Clare                                                                               50 622        88.3            11.7       
     Tipperary                                                                           21 735        89.5            10.5       
     Other counties                                                                      27 551        94.5             5.5        \<0.001
   Hospital region                                                                                                                
    Midwest                                                                              208 879       89.9            10.1       
    Northwest                                                                            242 767       91.9             8.1        \<0.001
   Location of medical supervision[^a^](#tblfn1){ref-type="table-fn"}                                                             
    ER                                                                                   87 193        85.7            14.3       
    GP                                                                                   266 766       98.5             1.5       
    IP                                                                                   46 584        61.6            38.4       
    OP                                                                                   35 463        86.6            13.4        \<0.001
   Measures of kidney function                                                                                                    
    Serum creatinine (µmol/L), median (IQR)                                              451 646    75.0 (22.0)     81.0 (43.0)    \<0.001
    eGFR[^b^](#tblfn2){ref-type="table-fn"} (mL/min/1.73 m[@gfy226-B2]), median (IQR)    451 646    95.1 (32.2)     73.7 (44.5)    \<0.001
    Plasma urea (mmol/L), median (IQR)                                                   439 217     5.2 (2.2)       9.5 (8.6)     \<0.001
   Baseline eGFR category[^c^](#tblfn3){ref-type="table-fn"}, %                                                                   
    ≥ 90                                                                                 259 669       95.0             5.0       
    60--89                                                                               148 223       90.7             9.3       
    30--59                                                                               39 149        71.7            28.3       
    15--29                                                                                3702         39.1            60.9       
    \<15                                                                                   903         25.0            75.0        \<0.001
   Measures of inflammation                                                                                                       
    C-reactive protein (SI), median (IQR)                                                48 474      3.4 (8.8)     37.0 (102.0)    \<0.001
    ESR, median (IQR)                                                                    141 905    9.5 (13.2)      32.0 (46.9)    \<0.001
    White blood count, median (IQR)                                                      416 369     7.3 (3.6)      10.4 (6.6)     \<0.001
    Lymphocyte count, median (IQR)                                                       401 969     1.9 (0.9)       1.3 (1.1)     \<0.001
    Neutrophil count, median (IQR)                                                       409 435     4.3 (2.9)       7.6 (6.4)     \<0.001
   Measures of nutrition                                                                                                          
    Serum albumin (g/L), mean (SD)                                                       282 547    39.2 (5.1)      30.8 (7.6)     \<0.001
    Total protein (mmol/L), mean (SD)                                                    255 996    68.4 (7.0)      61.1 (11.0)    \<0.001
   Measures of bone metabolism                                                                                                    
    Serum calcium (mmol/L), mean (SD)                                                    110 368     2.3 (0.1)       2.2 (0.2)     \<0.001
    Serum phosphorus (mmol/L), mean (SD)                                                 107 723     1.2 (0.3)       1.3 (0.5)     \<0.001
   Other metabolic biomarkers                                                                                                     
    Serum potassium (mmol/L), mean (SD)                                                  393 599     4.4 (0.5)       4.4 (0.8)     \<0.001
    Serum uric acid (μmol/L), median (IQR)                                               46 992    308.0 (116.0)   347.7 (175.0)   \<0.001
    Haemoglobin A1c (%), median (IQR)                                                    31 590      5.7 (1.3)       6.6 (2.0)     \<0.001
    Glucose (mmol/L), median (IQR)                                                       103 517     5.0 (0.9)       6.2 (2.7)     \<0.001
    Haemoglobin (g/dl), mean (SD)                                                        420 580    14.0 (1.6)      12.4 (2.3)     \<0.001

Location of medical supervision refers to the location of the patient when the test was conducted.

eGFR was based on the CKD-EPI equation \[[@gfy226-B19]\].

Excluding patients who received dialysis at baseline.

###### 

Patient characteristics at baseline by stage of AKI

  Variable                                                                                          *N*        Stage 1         Stage 2         Stage 3      P-value
  ----------------------------------------------------------------------------------------------- -------- --------------- --------------- --------------- ---------
  Patients, *n* (%)                                                                                40 786   33 155 (81.3)    4734 (11.6)     2897 (7.1)    
  Age at baseline (years), mean (SD)                                                               40 786    67.3 (18.3)     68.3 (17.5)     68.6 (16.7)     0.006
  Age group categories (years), %                                                                                                                          
   18--39                                                                                           4300        85.4             9.7             4.9       
   40--59                                                                                           6923        80.8            11.6             7.6       
   60--80                                                                                          18 526       80.6            11.9             7.5       
   \>80                                                                                            11 037       81.1            11.9             7.0        \<0.001
  Gender, %                                                                                                                                                
   Women                                                                                           19 965       80.8            12.4             6.7       
   Men                                                                                             20 821       81.7            10.8             7.4        \<0.001
  County of residence, %                                                                                                                                   
   Donegal                                                                                         10 806       80.7            11.9             7.4       
   Sligo                                                                                            4970        80.3            12.8             6.9       
   Leitrim                                                                                          2209        79.7            12.4             7.9       
   Limerick                                                                                         9177        82.2            11.3             6.5       
   Clare                                                                                            5930        81.5            11.6             6.9       
   Tipperary                                                                                        2287        82.9            10.7             6.4       
   All other counties                                                                               1524        82.4             9.6             8.0         0.002
  Hospital region, %                                                                                                                                       
   Midwest                                                                                         21 155       82.0            11.1             6.9       
   Northwest                                                                                       19 631       80.6            12.1             7.3         0.001
  Location of medical supervision[^a^](#tblfn4){ref-type="table-fn"}, %                                                                                    
   ER                                                                                              12 461       77.4            14.2             8.4       
   GP                                                                                               4084        83.3            11.4             5.2       
   IP                                                                                              17 897       83.7            10.0             6.3       
   OP                                                                                               4746        80.6            10.6             8.8        \<0.001
  Laboratory variables                                                                                                                                     
  Measures of kidney function                                                                                                                              
   Serum creatinine (μmol/L), median (IQR)                                                         40 786    81.5 (42.0)     73.0 (34.0)    117.0 (222.0)   \<0.001
   eGFR at baseline[^b^](#tblfn5){ref-type="table-fn"} (mL/min/1.73m[@gfy226-B2]), median (IQR)    40 786    73.8 (44.1)     82.0 (37.4)     46.2 (68.3)    \<0.001
   Urea (mmol/L), median (IQR)                                                                     39 641     8.7 (7.1)      12.2 (11.4)     23.8 (20.6)    \<0.001
  Baseline eGFR[^c^](#tblfn6){ref-type="table-fn"} (mL/min/1.73 m[@gfy226-B2])                                                                             
   ≥90                                                                                             12 911       81.7            13.7             4.5       
   60--89                                                                                          13 856       82.1            13.3             4.6       
   30--59                                                                                          11 088       85.3             9.8             4.9       
   15--29                                                                                           2254        75.8             1.3            22.8       
   \<15                                                                                             677          8.1             0.0            91.9        \<0.001
  Measures of inflammation                                                                                                                                 
   C-reactive protein (SI), median (IQR)                                                           13 669    32.2 (93.0)    61.0 (134.2)    64.9 (147.0)    \<0.001
   ESR, median (IQR)                                                                               24 209    30.0 (45.2)     37.0 (54.0)     44.8 (54.6)    \<0.001
   White blood count, median (IQR)                                                                 40 272    10.2 (6.2)      11.7 (8.8)      11.4 (8.5)     \<0.001
   Lymphocyte count, median (IQR)                                                                  39 273     1.3 (1.1)       1.1 (1.0)       1.0 (0.9)     \<0.001
   Neutrophil count, median (IQR)                                                                  40 051     7.4 (6.0)       8.8 (8.2)       8.8 (7.9)     \<0.001
  Measures of nutrition                                                                                                                                    
   Serum albumin (g/L), mean (SD)                                                                  36 359    31.3 (7.4)      29.1 (7.9)      28.4 (7.6)     \<0.001
   Total protein (mmol/L), mean (SD)                                                               32 969    61.4 (10.7)     59.9 (12.1)     59.7 (11.9)    \<0.001
  Measures of bone metabolism                                                                                                                              
   Serum calcium (mmol/L), mean (SD)                                                               26 748     2.2 (0.2)       2.2 (0.2)       2.1 (0.3)     \<0.001
   Serum phosphorus (mmol/L), mean (SD)                                                            28 888     1.2 (0.4)       1.3 (0.5)       1.7 (0.8)     \<0.001
  Metabolic biomarkers                                                                                                                                     
   Serum potassium (mmol/L), mean (SD)                                                             40 472     4.3 (0.7)       4.4 (0.9)       4.7 (1.1)     \<0.001
   Serum uric acid (umol/L), median (IQR)                                                           8036    343.0 (169.3)   338.0 (184.2)   412.4 (211.2)   \<0.001
   Haemoglobin A1c (%), median (IQR)                                                                7538      6.6 (2.0)       6.7 (2.2)       6.5 (1.8)      0.007
   Glucose (mmol/L), median (IQR)                                                                  13 590     6.2 (2.7)       6.3 (2.8)       6.3 (3.0)      0.367
   Haemoglobin (g/dl), mean (SD)                                                                   39 854    12.5 (2.2)      12.4 (2.4)      11.8 (2.6)     \<0.001

Location of medical supervision refers to the location of the patient when the test was conducted.

eGFR was based on the CKD-EPI equation \[[@gfy226-B19]\].

Excluding patients who received dialysis at baseline.

Temporal trends in incidence rates of AKI
-----------------------------------------

Incidence rates of AKI increased by at least 2-fold, from 5.48 in 2005 to 12.39 per 100 patient-years in 2014. For both men and women, a trend of increasing incidence was observed between 2005 and 2014 ([Figure 2a](#gfy226-F2){ref-type="fig"}). Adjusting for age, sex and location of supervision, incidence rates peaked in 2011 \[IRR 2.07 (95% CI 1.81--2.38)\] and plateaued thereafter ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S1](#sup1){ref-type="supplementary-material"}). Incidence rates were significantly higher for men than for women \[IRR 1.13 (95% CI 1.07--1.18)\] and increased significantly and substantially with advancing age. The adjusted IRR for patients \>80 years of age was \>11-fold higher than for patients ages 18--39 years ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S1](#sup1){ref-type="supplementary-material"}). Within each age category, men experienced significantly higher rates than women, and this pattern persisted over time ([Figure 2b](#gfy226-F2){ref-type="fig"}). For men and women, a relative plateauing of AKI rates was observed from 2010 to 2012, and this was most pronounced for patients in the age categories 60--79 and \>80 years.

![(**a**) Temporal trends in the incidence of AKI by sex in the health system. (**b**) Temporal trends in the incidence of AKI by age and sex in the health system. Dashed lines and error bars represent incidence rates with 95% CIs calculated from the direct method, whereas continuous lines and bands represent incident rates and 95% CIs calculated from Poisson regression.](gfy226f2){#gfy226-F2}

Temporal trends in incident rates by stage of AKI
-------------------------------------------------

Temporal trends in the incidence of AKI by severity stage are presented in [Table 3](#gfy226-T3){ref-type="table"} and [Figure 3](#gfy226-F3){ref-type="fig"}. Overall, Stage 1 AKI accounted for the greatest proportion of all AKI events. The pattern of annual growth in incidence was similar for Stages 1 and 2 AKI, with adjusted IRRs that increased significantly from 1.44 (95% CI 1.28--1.62) to 2.62 (2.32--2.96) and from 1.58 (95% CI 1.33--1.88) to 2.83 (2.32--3.46), respectively (P \< 0.001) ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S2](#sup1){ref-type="supplementary-material"}). In contrast, incidence rates of Stage 3 AKI increased from 2006 until 2012 \[peak IRR 2.27 (95% CI 2.01--2.57)\] and plateaued thereafter. Across all stages of AKI, rates were significantly higher in men than in women and increased with advancing age.

![(a) Temporal trends in the incidence rates of AKI by severity stage in the Irish health system. (b) Temporal trends in incidence rates of Stage 2 and Stage 3 AKI (magnified).](gfy226f3){#gfy226-F3}

###### 

Temporal trends in incidence rates of AKI in the Irish health system from 2005 to 2014

  Variable[^a^](#tblfn7){ref-type="table-fn"}                                   2005                   2006                   2007                   2008                   2009                   2010                   2011                    2012                   2013                   2014           P-value
  -------------------------------------------------------------------- ---------------------- ---------------------- ---------------------- ---------------------- ---------------------- ---------------------- ----------------------- ---------------------- ---------------------- ---------------------- ---------
  All patients                                                                 82 657                 60 869                 53 962                 45 713                 40 595                 38 540                 35 817                  33 644                 31 020                 28 829         
  AKI events, *n*                                                               4529                   4189                   4357                   4108                   4039                   4023                   4091                    4025                   3854                   3571          
  All patients                                                           5.48 (5.32--5.64)      6.88 (6.68--7.08)       8.07 (7.84--8.3)      8.99 (8.73--9.25)      9.95 (9.66--10.24)    10.44 (10.13--10.75)   11.42 (11.09--11.75)    11.96 (11.61--12.31)   12.42 (12.05--12.79)   12.39 (12.01--12.77)   \<0.001
   Stage 1                                                               4.41 (4.27--4.55)      5.58 (5.40--5.76)      6.61 (6.40--6.82)      7.25 (7.01--7.49)      8.09 (7.82--8.36)      8.58 (8.30--8.86)       9.33 (9.03--9.63)      9.68 (9.36--10.00)    10.05 (9.72--10.38)    10.11 (9.76--10.46)    \<0.001
   Stage 2                                                               0.60 (0.55--0.65)      0.83 (0.76--0.90)      0.92 (0.84--1.00)      1.08 (0.99--1.17)      1.15 (1.05--1.25)      1.14 (1.03--1.25)       1.29 (1.17--1.41)       1.4 (1.27--1.53)      1.52 (1.38--1.66)      1.46 (1.32--1.60)     \<0.001
   Stage 3                                                               0.46 (0.41--0.51)      0.46 (0.41--0.51)      0.54 (0.48--0.60)      0.65 (0.58--0.72)      0.70 (0.62--0.78)      0.72 (0.64--0.80)       0.80 (0.71--0.89)      0.88 (0.78--0.98)      0.85 (0.75--0.95)      0.81 (0.71--0.91)     \<0.001
  Men                                                                    6.06 (5.82--6.30)      7.67 (7.36--7.98)      9.00 (8.64--9.36)     10.77 (10.33--11.21)   10.82 (10.37--11.27)   11.47 (11.00--11.94)   12.48 (11.97--12.99)    12.02 (11.54--12.5)    12.37 (11.86--12.88)   13.22 (12.68--13.76)   \<0.001
   Stage 1                                                               4.91 (4.69--5.13)      6.24 (5.95--6.53)      7.48 (7.15--7.81)      8.70 (8.30--9.10)      8.75 (8.34--9.16)       9.47 (9.04--9.9)      10.27 (9.80--10.74)     9.74 (9.30--10.18)    10.11 (9.64--10.58)    10.90 (10.40--11.40)   \<0.001
   Stage 2                                                               0.62 (0.54--0.70)      0.87 (0.76--0.98)      0.94 (0.82--1.06)      1.26 (1.10--1.42)      1.21 (1.05--1.37)      1.15 (0.99--1.31)       1.35 (1.17--1.53)      1.32 (1.15--1.49)      1.34 (1.16--1.52)      1.42 (1.23--1.61)     \<0.001
   Stage 3                                                               0.53 (0.46--0.60)      0.55 (0.46--0.64)      0.58 (0.49--0.67)      0.81 (0.68--0.94)      0.86 (0.73--0.99)      0.86 (0.72--1.00)       0.86 (0.72--1.00)      0.96 (0.82--1.10)      0.91 (0.76--1.06)      0.90 (0.75--1.05)     \<0.001
  Women                                                                  5.01 (4.81--5.21)      6.24 (5.98--6.50)      7.29 (6.99--7.59)      7.66 (7.34--7.98)       9.22 (8.84--9.6)      9.56 (9.16--9.96)     10.53 (10.10--10.96)    11.90 (11.40--12.40)   12.48 (11.95--13.01)   11.49 (10.96--12.02)   \<0.001
   Stage 1                                                               4.01 (3.83--4.19)      5.04 (4.81--5.27)      5.88 (5.61--6.15)      6.18 (5.89--6.47)      7.54 (7.19--7.89)      7.82 (7.45--8.19)       8.54 (8.15--8.93)      9.61 (9.16--10.06)     9.99 (9.51--10.47)     9.27 (8.79--9.75)     \<0.001
   Stage 2                                                               0.59 (0.52--0.66)      0.80 (0.70--0.90)      0.91 (0.80--1.02)      0.95 (0.83--1.07)      1.11 (0.97--1.25)      1.14 (1.00--1.28)       1.23 (1.08--1.38)      1.49 (1.30--1.68)      1.71 (1.50--1.92)      1.51 (1.31--1.71)     \<0.001
   Stage 3                                                               0.41 (0.35--0.47)      0.39 (0.32--0.46)      0.51 (0.43--0.59)      0.53 (0.44--0.62)      0.58 (0.48--0.68)      0.60 (0.49--0.71)       0.76 (0.64--0.88)      0.80 (0.66--0.94)      0.78 (0.64--0.92)      0.71 (0.57--0.85)     \<0.001
  Age group (years)                                                                                                                                                                                                                                                                                           
   18--39                                                                1.55 (1.40--1.70)      1.74 (1.57--1.91)      2.18 (1.99--2.37)      2.26 (2.05--2.47)      2.53 (2.30--2.76)      2.67 (2.43--2.91)       3.00 (2.74--3.26)      2.92 (2.65--3.19)      2.95 (2.67--3.23)      2.33 (2.07--2.59)     \<0.001
   40--59                                                                2.50 (2.32--2.68)      3.21 (2.97--3.45)      4.24 (3.95--4.53)      4.81 (4.47--5.15)      5.09 (4.71--5.47)      5.93 (5.51--6.35)       6.43 (5.97--6.89)      6.55 (6.07--7.03)      6.84 (6.32--7.36)      7.28 (6.72--7.84)     \<0.001
   60--80                                                                9.53 (9.14--9.92)     14.45 (13.85--15.05)   18.23 (17.5--18.96)    21.25 (20.40--22.10)   23.45 (22.51--24.39)   24.56 (23.57--25.55)    27.9 (26.82--28.98)    28.59 (27.49--29.69)   29.08 (27.92--30.24)   30.16 (28.95--31.37)   \<0.001
   \>80                                                                 26.19 (24.95--27.43)   38.76 (37.02--40.5)    43.76 (41.85--45.67)   49.49 (47.38--51.6)    54.88 (52.72--57.04)   55.07 (52.85--57.29)    56.44 (54.18--58.7)    58.14 (55.86--60.42)   57.68 (55.47--59.89)   56.88 (54.56--59.20)   \<0.001
  Men (years)                                                                                                                                                                                                                                                                                                 
   18--39                                                                1.72 (1.48--1.96)      1.96 (1.69--2.23)      2.60 (2.29--2.91)      2.81 (2.45--3.17)      2.76 (2.40--3.12)      2.82 (2.44--3.20)       3.41 (2.99--3.83)      3.00 (2.62--3.38)      2.94 (2.54--3.34)      2.82 (2.42--3.22)     \<0.001
   40--59                                                                2.83 (2.55--3.11)      3.79 (3.42--4.16)      4.63 (4.19--5.07)      5.74 (5.19--6.29)      5.41 (4.85--5.97)      6.56 (5.94--7.18)       6.94 (6.26--7.62)      6.73 (6.07--7.39)      7.04 (6.32--7.76)      7.99 (7.20--8.78)     \<0.001
   60--80                                                               11.20 (10.58--11.82)   16.87 (15.91--17.83)   21.11 (19.97--22.25)   25.87 (24.47--27.27)   27.01 (25.55--28.47)   28.04 (26.52--29.56)   30.64 (29.02--32.26)    28.64 (27.15--30.13)   28.67 (27.10--30.24)   31.15 (29.52--32.78)   \<0.001
   \>80                                                                 27.74 (25.77--29.71)   42.04 (39.31--44.77)   48.03 (45.07--50.99)   61.11 (57.79--64.43)   59.25 (55.91--62.59)   59.68 (56.32--63.04)   61.62 (58.180--65.06)   57.58 (54.26--60.90)   56.66 (53.44--59.88)   58.47 (55.07--61.87)   \<0.001
  Women (years)                                                                                                                                                                                                                                                                                               
   18--39                                                                1.42 (1.23--1.61)      1.57 (1.35--1.79)      1.83 (1.59--2.07)      1.88 (1.63--2.13)      2.34 (2.04--2.64)      2.55 (2.23--2.87)       2.67 (2.34--3.00)      2.85 (2.48--3.22)      2.97 (2.58--3.36)      1.86 (1.54--2.18)     \<0.001
   40--59                                                                2.22 (1.99--2.45)      2.71 (2.41--3.01)      3.89 (3.51--4.27)      4.03 (3.60--4.46)      4.80 (4.29--5.31)      5.31 (4.75--5.87)       5.96 (5.35--6.57)      6.35 (5.65--7.05)      6.61 (5.85--7.37)      6.40 (5.61--7.19)     \<0.001
   60--80                                                                8.16 (7.68--8.64)     12.53 (11.78--13.28)   15.79 (14.85--16.73)   17.81 (16.75--18.87)   20.43 (19.21--21.65)   21.56 (20.26--22.86)     25.44 (24--26.88)     28.54 (26.92--30.16)   29.56 (27.84--31.28)   28.91 (27.11--30.71)   \<0.001
   \>80                                                                 25.11 (23.52--26.70)   36.44 (34.20--38.68)   40.69 (38.22--43.16)   42.27 (39.62--44.92)   51.87 (49.05--54.69)   51.67 (48.73--54.61)    52.8 (49.83--55.77)    58.64 (55.52--61.76)   58.59 (55.57--61.61)   55.53 (52.37--58.69)   \<0.001
  Location of medical supervision[^b^](#tblfn8){ref-type="table-fn"}                                                                                                                                                                                                                                          
   GP                                                                    0.71 (0.64--0.78)      1.04 (0.94--1.14)      1.38 (1.25--1.51)      1.33 (1.19--1.47)      1.64 (1.48--1.80)      1.74 (1.57--1.91)       2.20 (2.00--2.40)      2.28 (2.07--2.49)      2.72 (2.48--2.96)      2.36 (2.13--2.59)     \<0.001
   ER                                                                    8.21 (7.75--8.67)     10.85 (10.26--11.44)    12.25 (11.6--12.9)    13.84 (13.1--14.58)    15.01 (14.23--15.79)   15.60 (14.79--16.41)    17.77 (16.9--18.64)    18.73 (17.84--19.62)   18.82 (17.91--19.73)   19.79 (18.85--20.73)   \<0.001
   IP                                                                   28.76 (27.80--29.72)   32.85 (31.71--33.99)   34.3 (33.13--35.47)    39.58 (38.21--40.95)   40.78 (39.31--42.25)   44.64 (43.09--46.19)   46.28 (44.64--47.92)    49.30 (47.57--51.03)   46.44 (44.57--48.31)   46.17 (44.24--48.10)   \<0.001
   OP                                                                    6.46 (5.84--7.08)      7.54 (6.73--8.35)     10.32 (9.31--11.33)    14.05 (12.93--15.17)   17.3 (16.04--18.56)    18.37 (17.04--19.70)   17.44 (16.16--18.72)    16.62 (15.27--17.97)   16.83 (15.42--18.24)   17.73 (16.25--19.21)   \<0.001
  Hospital region                                                                                                                                                                                                                                                                                             
   Northwest region                                                      4.18 (4.02--4.34)      6.14 (5.89--6.39)      7.47 (7.16--7.78)      8.14 (7.79--8.49)      9.77 (9.36--10.18)     9.51 (9.08--9.94)     10.94 (10.47--11.41)    11.71 (11.22--12.2)    12.79 (12.24--13.34)   13.73 (13.14--14.32)   \<0.001
   Midwest region                                                        8.30 (7.97--8.63)      7.97 (7.63--8.31)      8.74 (8.39--9.09)      9.85 (9.46--10.24)    10.12 (9.71--10.53)    11.25 (10.82--11.68)   11.87 (11.41--12.33)    12.20 (11.71--12.69)   12.11 (11.62--12.60)   11.28 (10.79--11.77)   \<0.001
  County of residence                                                                                                                                                                                                                                                                                         
   Donegal                                                               4.80 (4.55--5.05)      7.15 (6.77--7.53)      8.39 (7.93--8.85)      9.10 (8.58--9.62)     10.98 (10.36--11.6)    10.93 (10.28--11.58)   11.55 (10.88--12.22)    13.55 (12.80--14.30)   13.17 (12.39--13.95)   14.68 (13.82--15.54)   \<0.001
   Sligo                                                                 3.97 (3.67--4.27)      6.25 (5.76--6.74)      8.38 (7.71--9.05)       9.19 (8.4--9.98)     11.05 (10.11--11.99)   10.91 (9.91--11.91)    14.26 (13.09--15.43)    13.83 (12.61--15.05)   17.56 (16.14--18.98)   18.24 (16.75--19.73)   \<0.001
   Limerick                                                              8.97 (8.42--9.52)      8.61 (8.04--9.18)      9.02 (8.47--9.57)     10.74 (10.11--11.37)   10.54 (9.89--11.19)    11.55 (10.87--12.23)   12.69 (11.94--13.44)    13.57 (12.78--14.36)   13.20 (12.39--14.01)   12.78 (11.96--13.60)   \<0.001
   Leitrim                                                               3.83 (3.36--4.30)      6.10 (5.35--6.85)      6.84 (5.95--7.73)      8.98 (7.86--10.10)    12.00 (10.60--13.40)    9.62 (8.33--10.91)    13.38 (11.80--14.96)    11.19 (9.75--12.63)    14.45 (12.63--16.27)   16.21 (14.18--18.24)   \<0.001
   Clare                                                                 8.13 (7.49--8.77)      8.02 (7.37--8.67)      9.46 (8.75--10.17)    11.83 (10.97--12.69)   11.84 (10.94--12.74)   14.29 (13.3--15.28)    15.31 (14.23--16.39)    15.22 (14.09--16.35)   16.11 (14.94--17.28)   13.21 (12.08--14.34)   \<0.001
   Tipperary                                                            10.39 (9.25--11.53)     9.07 (7.99--10.15)    10.03 (8.89--11.17)     8.72 (7.60--9.84)     11.44 (10.08--12.80)   11.7 (10.33--13.07)     11.21 (9.81--12.61)    10.43 (8.99--11.87)    12.20 (10.64--13.76)   11.54 (9.95--13.13)     0.001
   All other counties                                                    3.68 (3.10--4.26)      4.96 (4.20--5.72)      5.42 (4.59--6.25)      5.07 (4.24--5.90)      6.04 (5.07--7.01)      6.19 (5.24--7.14)       5.73 (4.82--6.64)      5.82 (4.92--6.72)      6.65 (5.67--7.63)      7.29 (6.23--8.35)     \<0.001

Incidence rates expressed at events per 100 patients at risk with 95% CIs.

Location of medical supervision refers to the location of the patient when the test was conducted.

AKI trends by location of supervision
-------------------------------------

Incidence rates of AKI increased significantly from 2005 to 2014 across all health care settings as shown in [Table 3](#gfy226-T3){ref-type="table"}. Patients classified as IP recorded the highest incidence rates of AKI compared with patients observed in the ER, GP or OP settings. With adjustment for age, sex and calendar year, IP had incidence rates that were 15.5 times (13.66--17.63) greater than those in the GP setting ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Table S1](#sup1){ref-type="supplementary-material"}).

Factors associated with first AKI
---------------------------------

The results of univariate and multivariable associations of first AKI are shown in [Table 4](#gfy226-T4){ref-type="table"}. In univariate analysis, the OR of AKI increased in a monotonic fashion with each successive year. With adjustment for demographic characteristics, illness indicators, county of residence and location of supervision, patients who entered the health system in 2014 were significantly more likely to experience an AKI compared with those in 2005 \[OR 4.36 (95% CI 3.90--4.87), P \< 0.001\]. To determine whether this relationship varied by AKI stage, we repeated the analysis stratified by AKI stage in separate logistic models. In each of these additional analyses the pattern was similar with significantly higher ORs for AKI Stages 1--3 in 2014 compared with the referent 2005, as shown in [Figure 4](#gfy226-F4){ref-type="fig"}. Increasing age \[OR 1.25 (95% CI 1.24--1.26)\] and male gender \[OR 1.28 (95% CI 1.22--1.35)\] were significantly associated with AKI incidence in the multivariable model. Compared with patients in GP, patients managed as IP \[OR 19.11 (95% CI 17.69--20.64)\], attending the ER \[OR 5.97 (95% CI 5.56--6.42)\] or OP \[OR 4.37 (95% CI 4.02--4.75)\] were significantly more likely to experience an AKI event. Incidence rates of AKI also varied significantly by county of residence, which was not explained by patient-level factors or location of medical supervision, as shown in [Table 4](#gfy226-T4){ref-type="table"}. The final model had excellent discrimination with a C-statistic of 0.93. Significant interactions were observed between age and sex (P \< 0.001) and sex and calendar year (P \< 0.001). Incorporating these interactions in the model indicated that the likelihood of AKI was significantly higher for men than for women in the earlier time periods but this difference had almost disappeared in later years ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Figure S2](#sup1){ref-type="supplementary-material"}), particularly for those \>50 years of age ([Supplementary data](#sup1){ref-type="supplementary-material"}, [Figure S3](#sup1){ref-type="supplementary-material"}).

![Adjusted OR for the first AKI event by the stage of AKI across calendar years in the Irish health system. The relationship between calendar year and the OR of AKI is modelled separately for AKI Stages 1--3 with year 2005 as the referent. In each model, covariates for adjustment include age, sex, baseline GFR estimated using the CKD-EPI equation, county of residence, location of medical supervision, laboratory measures of illness (haemoglobin, serum albumin, white blood cell count, serum potassium, serum calcium and serum phosphorus concentration) and calendar year. P \< 0.001 for each year compared with referent 2005.](gfy226f4){#gfy226-F4}

###### 

Factors associated with the first AKI in the Irish health system

  Variable                                                                   Unadjusted OR (95% CI)   P-value   Adjusted OR (95% CI)[^a^](#tblfn9){ref-type="table-fn"}   P-value
  ------------------------------------------------------------------------- ------------------------ --------- --------------------------------------------------------- ---------
  Age (per 5 years)                                                            1.41 (1.40--1.41)      \<0.001                      1.25 (1.24--1.26)                      \<0.001
  Men (versus women)                                                           1.22 (1.20--1.25)      \<0.001                      1.28 (1.22--1.35)                      \<0.001
  Baseline eGFR[^b^](#tblfn10){ref-type="table-fn"} (per 5 unit decrease)       1.17 (1.17--1.17      \<0.001                      1.01 (1.01--1.02)                      \<0.001
  County of residence                                                                                                                                                    
   Donegal (reference)                                                                1.00              --                               1.00                               --
   Sligo                                                                       0.97 (0.93--1.00)       0.050                       1.09 (1.00--1.18)                       0.040
   Leitrim                                                                     0.92 (0.88--0.97)      \<0.001                      0.88 (0.79--0.98)                       0.020
   Limerick                                                                    1.23 (1.19--1.26)      \<0.001                      1.70 (1.60--1.81)                      \<0.001
   Clare                                                                       1.33 (1.28--1.37)      \<0.001                      1.91 (1.74--2.08)                      \<0.001
   Tipperary                                                                   1.18 (1.12--1.24)      \<0.001                      0.89 (0.78--1.01)                       0.080
   All other counties                                                          0.59 (0.55--0.62)      \<0.001                      0.34 (0.31--0.38)                      \<0.001
  Location of medical supervision[^c^](#tblfn11){ref-type="table-fn"}                                                                                                    
   GP (reference**)**                                                                 1.00              --                               1.00                               --
   ER                                                                         10.72 (10.34--11.12)    \<0.001                      5.97 (5.56--6.42)                      \<0.001
   IP                                                                         40.13 (38.70--41.60)    \<0.001                    19.11 (17.69--20.64)                     \<0.001
   OP                                                                          9.94 (9.52--10.38)     \<0.001                      4.37 (4.02--4.75)                      \<0.001
  Calendar year                                                                                                                                                          
   2005 (reference)                                                                   1.00              --                               1.00                               --
   2006                                                                        1.27 (1.22--1.33)      \<0.001                      1.65 (1.49--1.83)                      \<0.001
   2007                                                                        1.52 (1.45--1.58)      \<0.001                      1.93 (1.74--2.13)                      \<0.001
   2008                                                                        1.70 (1.63--1.78)      \<0.001                      2.66 (2.40--2.95)                      \<0.001
   2009                                                                        1.91 (1.82--1.99)      \<0.001                      2.81 (2.54--3.11)                      \<0.001
   2010                                                                        2.01 (1.92--2.10)      \<0.001                      3.09 (2.78--3.42)                      \<0.001
   2011                                                                        2.22 (2.13--2.33)      \<0.001                      3.70 (3.33--4.10)                      \<0.001
   2012                                                                        2.34 (2.24--2.45)      \<0.001                      4.05 (3.64--4.50)                      \<0.001
   2013                                                                        2.45 (2.34--2.56)      \<0.001                      4.09 (3.67--4.56)                      \<0.001
   2014                                                                        2.44 (2.33--2.55)      \<0.001                      4.36 (3.90--4.87)                      \<0.001

Multivariable models show adjusted ORs and corresponding 95% CIs. Model is adjusted for the following measures assessed at baseline: age, sex, baseline GFR estimated using CKD-EPI equation, county of residence, location of medical supervision, laboratory measures of illness (haemoglobin, serum albumin, white blood cell count, serum potassium and serum urea concentration) and calendar year; C-statistic = 0.95.

eGFR was based on the CKD-EPI equation \[[@gfy226-B19]\].

Location of medical supervision refers to the location of the patient when the laboratory test was conducted.

SENSITIVITY ANALYSIS
====================

We repeated the entire analysis, restricting the sample to patients who had creatinine values recorded prior to the AKI episode. This yielded a final cohort of 449 190 who experienced 30 836 (6.9%) AKI episodes and had similar demographic and clinical characteristics to those of the original cohort. Similar to before, we found that incidence rates increased with each successive year and that the patterns of association mirrored those of the primary analysis ([Figure 5](#gfy226-F5){ref-type="fig"} and [Supplementary data](#sup1){ref-type="supplementary-material"}, [Tables S3A](#gfy226-T3){ref-type="table"} and S3B). Similarly, substituting the mean for the median serum creatinine in the assessment of baseline creatinine or using the MDRD equation instead of the CKD-EPI equation in estimating baseline GFR, we found the same qualitative trends were observed and these are summarized in [Supplementary data](#sup1){ref-type="supplementary-material"}, [Tables S3--S5](#sup1){ref-type="supplementary-material"}.

![Temporal trends in the incidence of AKI by severity stage in the Irish health system. The solid line represents data from primary analysis and the dashed line represents data from the first sensitivity analysis.](gfy226f5){#gfy226-F5}

DISCUSSION
==========

To our knowledge, this is the first study to describe annual trends in the frequency of AKI by severity staging in the health system and to characterize differences across major health care settings. Using a laboratory-based definition of AKI, we demonstrated a trend of increasing incidence of AKI over the past decade, a pattern that was observed across all AKI Stages 1--3. The rising trend was observed for both men and women and across all age groups, although the greatest increases were observed in elderly patients. Moreover, we identified the IP setting as the most common location for AKI occurrence even though the rates were also common in other key locations such as the ER and OP settings. Several patient- and facility-levelcharacteristics were associated with the occurrence of a first AKI event, including older age, male gender, baseline kidney function, county of residence and location of medical supervision, although these did not sufficiently account for the rising annual trend in AKI incidence.

We highlight a pattern of increasing incidence of AKI in the Irish health system that was clearly manifested across several locations of patient supervision. Increases in the absolute rates of AKI were observed for men and women and in all age groups, accounting for a more than 2-fold increase in rates from 2005 to 2014. Given the mounting evidence that connects AKI with substantial adverse impact on both short- and long-term clinical outcomes \[[@gfy226-B4], [@gfy226-B10]\], it is imperative that we pay attention to these epidemiological trends. A fundamental challenge in all health systems is early detection of disease so that we can develop and implement effective prevention strategies \[[@gfy226-B17], [@gfy226-B29], [@gfy226-B30]\]. In this study we identified key clinical locations in the health system where incidence rates of AKI were highest. By and large, the IP setting was the most common site of AKI occurrence, which is not surprising given that it accommodates the sickest patients. Patients within the health system and needing admission to an IP ward were almost 20-fold more likely to develop an AKI. The pattern of annual incidence increased to a peak in 2012 and appeared to plateau thereafter. Our analysis would suggest that targeting of locations where AKI is most likely to occur would be a primary goal. Through early detection strategies including electronic alert systems and adoption of early treatment interventions, it is likely that many AKI events could be prevented and more effectively managed \[[@gfy226-B30]\]. Our analysis also suggests that other locations should also be targeted, especially the ER and outpatient clinics. These are critical points where patients interact with their physicians and multidisciplinary teams to management acute and chronic conditions.

Our study has shed new light not only on the overall pattern of AKI incidence over time but also on important trends according to the severity of AKI. Of particular interest is the finding that the greatest absolute increases in AKI incidence were accounted for by increases in AKI Stage 1. From 2005 to 2014, absolute rates of AKI Stage 1 increased from 4.4 to 11.1%, while the growth in Stage 2 (from 0.60 to 1.46%) and Stage 3 (from 0.46 to 0.81%) were less impressive. This would suggest that greater should attention be given to these 'minor' AKI events and their determinants. Equally important, the pattern of AKI incidence differed by severity stage over time. Indeed, on comparing IRR across calendar years, the IRR for Stage 3 AKI appears to peak in 2012 at 2.27 (95% CI 2.01--2.57) and declined thereafter to 2.03 (95% CI 1.75--2.36) compared with AKI Stages 1 and 2. This might suggest that the driving forces for Stage 3 AKI are better managed, including earlier recognition and management of AKI Stages 1 and 2 and thereby less transition to Stage 3.

Our study has several strengths that merit comment. Our analysis depended solely on a laboratory-based approach. The measurement of serum creatinine was based on assays that are traceable to IDMS. The diagnosis of AKI using KDIGO criteria was determined based solely on serum creatinine concentrations from regional laboratory systems, thereby avoiding the need for hospital-based coding. Therefore our analysis provides a more accurate reflection of the true event rate of AKI in the health system \[[@gfy226-B22]\]. An equally important advantage of our study was the availability of serum creatinine measurements measured prior to the AKI event in 87% of all patients. Accordingly we were able to ascertain the baseline stage of CKD and baseline creatinine to define the presence and severity of AKI. Finally, our study was strengthened by the use of large regional samples that included 451 646 patients with extensive demographic, laboratory and facility-level data captured over time. Despite these strengths, some weaknesses were apparent. First, we did not have available data on comorbidity and medical procedures, and therefore adjustment for case mix depended on laboratory parameters to reflect the presence and severity of illness. Nevertheless, the final set of demographic characteristics and clinical and geographic variables included in our model were important enough to yield a C-statistic of 0.93. Second, our analysis lacked data on hospital admission and length of stay, information that would have further clarified our understanding of community and hospital-based AKI events. Instead, we were able to pinpoint with certainty the exact location of medical supervision from blood request forms completed by the supervisory physicians. Third, it is possible that underreporting of Stage 3 AKI events may have occurred, as our analysis did not capture acute dialysis-requiring AKI. Similarly, underreporting of Stages 2 and 3 events may have resulted from our dependence on creatinine values near the initiation of an AKI episode rather than on maximal values. Fourth, longitudinal tracking of patients in the Irish health system was based on a probabilistic matching strategy rather than a unique identifier \[[@gfy226-B25]\]. Finally, we readily acknowledge the limitations of serum creatinine as a diagnostic marker of AKI, as it has been shown to be affected by factors independent of GFR such age, sex, race, body size, diet and certain drugs \[[@gfy226-B31]\].

Within the Irish health system, we demonstrate patterns of increasing incidence of AKI from 2005 to 2014. For men and women from all age groups, incident rates of AKI increased over time. Increasing incidence was observed for all stages of AKI, but most of the increase was accounted for by accelerated growth of Stage 1 AKI. AKI events were more common in the key areas of medical supervision and physical locations that could potentially be targeted for early detection and prevention programmes. Changes in patient- and facility-level characteristics were significantly associated with an increasing incidence of AKI, however, adjustment for these did not fully account for the observed growth. Effective management of AKI in health systems requires robust surveillance systems embedded within the health system to track the frequency and impact of AKI events over time as well as monitor the effectiveness of preventive strategies in high-risk clinical settings. The goal of the National Kidney Disease Surveillance System in Ireland is to better understand the evolving landscape of AKI in the Irish health system, its determinants and outcomes, resource utilization and costs in order to improve both patient outcomes and health system performance.
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